For NZ residents only

No Results Found!

Home | Nucala

NUCALA is an add-on treatment for relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over.1

Home | NUCALA can help offer*

Based on a 52-weeks clinical study, when compared with placebo. Number of participants in the Nucala group=68; number of participants in the placebo group=68. Your experience may be different.

Home | What is Eosinophilic Granulomatosis with Polyanglitis (EGPA)?

EGPA is a condition where people have inflammation of the blood vessels (vasculitis) associated with too many eosinophils (a type of white blood cell) in the blood and tissues.

Home|The NUCALA pre-filled pen

Curious about taking your medication at home? Learn about a 4-weekly, at-home option.

What is Eosinophilic Granulomatosis with Polyangiitis (EGPA)?

Eosinophilic granulomatosis (gran-u-lo-ma-toe-sis) with polyangiitis (poly-angi-i-tis) (EGPA) is a condition where people have inflammation of the blood vessels (vasculitis) associated with too many eosinophils (a type of white blood cell) in the blood and tissues.

What is EGPA?|EGPA symptoms may include

Fatigue,Difficulty Breathing etc.

What is EGPA?|Why NUCALA?

If you’re ready for a different kind of treatment for your EGPA, see what NUCALA can do for you.

About NUCALA | What is NUCALA?

NUCALA is a medication indicated as an add-on treatment for relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over.

About NUCALA | How does NUCALA work?

NUCALA contains the medicine mepolizumab (me-poh-liz-ooh-mab), which works by blocking a protein called interleukin-5 (IL-5).1,11 By blocking the action of IL-5, NUCALA:11

About NUCALA | How does NUCALA work | What are the benefits of NUCALA?

Based on a 52-weeks clinical study, patients treated with NUCALA in combination with other medicines experienced

About NUCALA | How does NUCALA work | How is NUCALA taken?

NUCALA is given as 3 injections, under the skin (subcutaneous), once every 4 weeks for EGPA patient.

About NUCALA | How does NUCALA work | How will I receive NUCALA?

You might have already had your first NUCALA injections, but if you haven’t, you probably want to know what to expect.

About NUCALA | How does NUCALA work | Planning for you next dose

You might wonder how to remember your injection appointments.

About NUCALA | How does NUCALA work | What is the recommended dose of NUCALA for EGPA?

Adults (≥18 years of age): 300 mg, given as 3 injections under the skin (subcutaneous) every 4 weeks.1

About NUCALA | How does NUCALA work | Every 4 weeks. At home. On your time.

NUCALA pre-filled pen is a 4 weekly injection as an add-on treatment for relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over.

About NUCALA | How does NUCALA work | Designed with you in mind

Don’t like needles? With the NUCALA pre-filled pen, you don’t have to see the needle.

About NUCALA | How does NUCALA work | At-home convenience

After you learn how to properly self-inject from your doctor, you can do it on your own in the comfort of your own home with the NUCALA pre-filled pen.

About NUCALA | How does NUCALA work | Self-inject with confidence

Once you and your specialist decide that the NUCALA pre-filled pen is right for you, you will be given information on how to properly inject and how to monitor for allergic reactions.

About NUCALA | How does NUCALA work | The NUCALA pre-filled pen

Step by step instructions for using the pre-filled pen.

Risk & side effects|Safety information about NUCALA

Please refer to the NUCALA Consumer Medicine Information for more details.

Risks and side effects | Storage information

Keep NUCALA and all medicines out of the reach of children.

Risks and side effects | Warnings

Keep NUCALA and all medicines out of the reach of children.

Risks and side effects |Frequently asked questions

At-home Administration,Pre-filled Pen.

Resources | Doctor Discussion Guide

Doctor Discussion Guide

Resources | Patient Booklet

Patient Booklet

doctor discussion guide icon

Ready to talk to your doctor?

Download the doctor discussion guide to keep the conversation on track.
Nucala Important Safety Information:1

Contraindications: hypersensitivity to mepolizumab or to any of the excipients.

Warnings & Precautions: EGPA: NUCALA treated patients may experience a return of EGPA symptoms upon cessation of NUCALA and other EGPA treatments may need to be increased accordingly if NUCALA is discontinued as patients may decrease their other EGPA treatments during NUCALA treatment.

Adverse Reactions: headache, joint pain, nausea, sinusitis, upper respiratory tract infection, diarrhoea, vomiting, injection site reaction. Please refer to the Nucala Consumer Medicine Information for more details.

References:
  1. GlaxoSmithKline New Zealand. Nucala Data Sheet. GSK NZ; 2023. Available at https://medsafe.govt.nz/profs/Datasheet/n/nucalainj.pdf. Last accessed 18/11/2024
  2. Fagni, F.; et al. (2021). Front Med. 24(8):627776.
  3. Fijolek, J. & Radzikowska, E. (2023). Front Med 10:1145257.
  4. Gioffredi, A.; et al. (2014). Front Immunol 5:549.
  5. Doubelt, I.; et al. (2021). ACR OpenRheumatol. 3(6): 404-412.
  6. Mohammad, N. & Ghazali, W.S.W. (2017). BMJ Case Rep.
  7. Cottin, V.; et al. (2016). Europ Respir Jour 48:1429-1441.
  8. Low, M.C.; et al. (2019). Int Forum Allergy Rhinol. 10(2): 217-222.
  9. Pagnoux, C., et al. (2007). Curr Opin Rheumatol 19(1): 25-32.
  10. Wechsler M.E.; et al. (2017) N Engl J Med. 376:1921-1932.
  11. GlaxoSmithKline New Zealand. Nucala Consumer Medicine Information. GSK NZ; 2023. Available at https://www.medsafe.govt.nz/Consumers/CMI. Last accessed 18/11/2024
  12. Khoury P; et al. (2014) Nat Rev Rheumatol.10;474-483.
  13. Vaglio A; et al. (2013) Allergy. 68;261-73.
  14. Steinfeld J; et al. (2019) The Journal of Allergy and Clinical Immunology 143(6);2170-2177.
  15. Wechsler ME; et al. (2017) N Engl J Med. 376;1921-1932 (supplementary).
  16. Bernstein D; et al. (2019) Journal of Asthma. 28;1-12.
  17. Klion AD; et al. (2020) Annual Review of Pathology: Mechanisms of Disease. 15;179-209
Nucala (mepolizumab 100 mg) is a Prescription Medicine, available as a 100 mg/mL pre-filled pen (auto-injector). Each pre-filled pen delivers 100 mg mepolizumab in 1 mL. Nucala is used as an add-on treatment for; severe eosinophilic asthma in patients 12 years and over, severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to intranasal corticosteroids in adult patients 18 years and older, relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over, and in adult patients with inadequately controlled hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause. Nucala is given by injection under your skin (subcutaneous). Nucala is fully funded for severe eosinophilic asthma and EGPA only; Special Authority criteria apply. Use strictly as directed. Nucala has risks and benefits. Do not stop taking your other asthma medications including inhaled and /or oral steroid asthma medications. Tell your doctor if: you have a parasitic (helminth) infection; you are taking prescription and over-the-counter medicines, vitamins, and herbal supplements; you are pregnant or plan to become pregnant; you are breastfeeding or plan to breastfeed. Nucala does not treat acute asthma symptoms, such as sudden asthma attack. Tell your healthcare professional or get emergency help immediately if you have any of the following symptoms of an allergic reaction: swelling of your face, mouth, and tongue, breathing problems, fainting, dizziness, feeling light-headed (low blood pressure), rash or hives. Side effects: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and fatigue. Serious side effects may include allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your injection of Nucala. Allergic reactions can sometimes happen hours or days after you get a dose of Nucala. Herpes zoster infections that can cause shingles have happened in people who received Nucala. If symptoms continue or you have side effects, see your doctor, pharmacist or health care professional. For more information, see Nucala Consumer Medicine Information at www.medsafe.govt.nz. Ask your doctor if Nucala is right for you. Normal doctor’s charges apply. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.

This website is intended for residents of New Zealand only.

Any information provided on this website should be discussed with a healthcare professional and does not replace a healthcare professional’s advice.